Jonathan Schatz's Avatar

Jonathan Schatz

@drjonschatzmd.bsky.social

Professor of Medicine, Sylvester Comprehensive Cancer Center, University of Miami. Lymphoma clinician and researcher, investigating treatment resistance and novel therapies. Opinions are my own.

162 Followers  |  109 Following  |  62 Posts  |  Joined: 23.11.2024  |  1.942

Latest posts by drjonschatzmd.bsky.social on Bluesky

Preview
Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline - BioDrugs Since blinatumomab’s approval as the first bispecific antibody (BsAb) in cancer therapy, these immunomodulatory agents have achieved substantial success in lymphoid malignancies. A decade after provis...

Catch up on bispecifics with our new review, just published online. @springernature.com
link.springer.com/article/10.1...

02.08.2025 21:22 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy Abstract. Cancers co-opt stress response pathways to drive oncogenesis, dodge immune surveillance, and resist cytotoxic therapies. Several of these pathways also provide protection from ferroptosis, a...

Proud to announce online publication. Amazing work by Paola Manara and the whole Schatz lab. And congrats to @aacrjournals.bsky.social for Cancer Research Impact Factor now 16.6!
aacrjournals.org/cancerres/ar...

01.08.2025 13:43 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Miami Cubans get it.

05.04.2025 17:49 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0
Post image

Thousands in Downtown Miami at the Hands-Off protest

05.04.2025 17:39 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

After receiving this score yesterday on our R01 at the National Cancer Institute, I can only express my deepest gratitude to the dedicated, hard-working employees at NIH for all they do!

05.04.2025 12:15 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Letter found among my late father's papers from his former post-doc mentor

04.04.2025 18:40 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

This Seth approves.

23.03.2025 23:02 β€” πŸ‘ 907    πŸ” 97    πŸ’¬ 29    πŸ“Œ 10
Post image

Amazing job by @paolamanara.bsky.social in her PhD defense this morning. Congratulations Dr. Manara, PhD.

24.03.2025 17:04 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

Major Congratulations to Schatz lab graduate Caroline Coughlin matching Friday at her No. 1 choice for residency!! @bostonchildrens.bsky.social

24.03.2025 17:01 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
RHOA Loss of Function Impairs the IFNΞ³ Response and Promotes CD19 Antigen Escape to Drive CAR-T Resistance in Diffuse Large B-cell Lymphoma CD19-directed chimeric antigen receptor (CAR)-T cells are breakthrough therapies for aggressive B-cell lymphomas, but less than half of patients achieve durable responses. We previously showed through...

Our latest Preprint is up on bioRxiv. Check out exciting new insights on CAR-T resistance in LBCL
doi.org/10.1101/2025...

06.03.2025 13:15 β€” πŸ‘ 3    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
I just gave to Al Green! Show your support with a contribution.

secure.actblue.com/donate/al-gr...

06.03.2025 13:11 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
I just gave to Al Green! Show your support with a contribution.

secure.actblue.com/donate/al-gr...

06.03.2025 13:10 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
NIH ban on renewing senior scientists adds to assaults on its in-house research Policy follows firings of tenure-track scientists and suspension of training programs

This will have tragic consequences on medical research. #NIH ban on renewing senior scientists adds to assaults on its in-house research | Science | AAAS www.science.org/content/arti...

27.02.2025 18:41 β€” πŸ‘ 6    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

Our grad student Olivia Lightfuss' confocal microscopy images displayed in our Office of Graduate Studies. Nice work Liv! @austinnewsam.bsky.social @paolamanara.bsky.social

27.02.2025 15:06 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image Post image Post image

Tomorrow is #RareDiseaseDay! Did you know that a disease is considered rare when it affects fewer than 1 in 2,000 people? But with 7,000+ rare diseases worldwide, they collectively affect 300M+ people.

Support the ASH Research Awards Fund πŸ”— https://bit.ly/3XjCFNr

#hematology #HemeSky #BloodSky

27.02.2025 13:20 β€” πŸ‘ 12    πŸ” 5    πŸ’¬ 0    πŸ“Œ 0

Study section I was scheduled to serve on Thursday and Friday this week, countless hours spent in preparation by me and the rest of the members, canceled today with no explanation given. Why would Putin have ordered this?

26.02.2025 01:00 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

With Sylvester Director Stephen Nimer at the 15 Dolphins Cancer Challegne today. 99 miles!

A great way to support Cancer Research in Desperate Times!

dolphinscancerchallenge.com/index.cfm?fu...

22.02.2025 21:31 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

We need a new option. Facing a president systematically destroying their country and whose popularity is low and sinking, they have NOTHING to offer. Democratic cowardice got us into this mess, beginning with Obama (the cowardly lion) and moving forward. They know no other way...

21.02.2025 20:38 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

Flat Earthers? Don't tempt them

21.02.2025 20:32 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

FOIA incoming

21.02.2025 20:29 β€” πŸ‘ 2    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Post image

DOGE By The Numbers
theonion.com/doge-by...

21.02.2025 02:00 β€” πŸ‘ 14325    πŸ” 2871    πŸ’¬ 184    πŸ“Œ 83

He's a parody of himself

03.02.2025 16:37 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Sylvester Comprehensive Cancer Center

Thanks to the Cutaneous Lymphoma Foundation for listing our multidisciplinary skin lymphoma clinic. This clinic staffed by me and Georgios Pongas from hematology and Scott Elman from dermatology is an incredible resource for patients affected by these diseases!
www.clfoundation.org/sylvester-co...

03.02.2025 15:14 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

BLUETORIAL 6) Read our paper for the fascinating mechanisms of how this all works. Incredible work by our first and many contributing authors over the past several years!

03.02.2025 14:10 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

BLUETORIAL 5) We find, however, that a combination of BTK inhibitor, in particular the potent non-covalent compound pirtobrutinib, and venetoclax overcomes resistance. BTK therefore maintains a role in driving resistance even when CBM is activated downstream by BCL10 mutations.

03.02.2025 14:09 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

BLUETORIAL 4) BCL10 mutations cluster in BN2/C1 DLBCL cases, which are known to be resistant to BTK inhibitors. We find that BCL10 mutations, in addition to driving BTK inhibitor resistance, drive resistance to multiple other classes of drug, including the BCL2 inhibitor venetoclax

03.02.2025 14:07 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

BLUETORIAL 3) Our work now elaborates on the signaling and therapeutic consequences of these activating mechanisms. Detailed gene-expression and mechanistic work shows how mutant-BCL10 mediated CBM activation establishes a cytokine-reinforced positive-feedback loop of lymphomagenesis

03.02.2025 14:04 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

BLUETORIAL 2) Amazing work by the Ari Melnick lab demonstrated both these classes of mutation activate the protein's role in signaling by way of the BCL10-CARD11-MALT1 (CBM) complex. R58Q stablizes signaling, the truncations remove an inhibitory domain allowing spontaneous complex activation.

03.02.2025 14:01 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0

Bluetorial 1) BCL10 is recurrently mutated in DLBCL cases with a fascinating pattern: The N-terminal CARD domain has a hotspot missense mutation (R58Q) consistent with gain of function, while the C-terminal is recurrently truncated consistent with loss of function.

03.02.2025 13:59 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Preview
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax - Blood Cancer Journal Blood Cancer Journal - Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax

We're excited to announce online publication of our new article in Blood Cancer Journal @natureportfolio.nature.com

Major Congratulations to our co-first authors Caroline Coughlin and Dhanvantri (Davi) Chahar.

"Bluetorial" overview follows in my replies.

www.nature.com/articles/s41...

03.02.2025 13:55 β€” πŸ‘ 1    πŸ” 0    πŸ’¬ 5    πŸ“Œ 0

@drjonschatzmd is following 20 prominent accounts